Research analysts at Guggenheim began coverage on shares of Compass Therapeutics (NASDAQ:CMPX – Get Free Report) in a research note issued on Monday, MarketBeat reports. The firm set a “buy” rating ...

Fresh Tracks Therapeutics, Inc. ("Fresh Tracks" or the "Company") announced today an update on its previously announced, planned dissolution and its process for distributing cash to its stockholders.

Enliven Therapeutics, Inc. (Enliven or the Company) , a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that ...

Fintel reports that on February 24, 2025, Guggenheim initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Buy recommendation. Analyst Price Forecast Suggests 266.05% Upside As of February ...

Compass Therapeutics (CMPX) stock was up 8% in afternoon trading Monday after Guggenheim initiated coverage of the stock with a buy rating ahead of upcoming data. Read more here.

Compass Therapeutics' lead candidate, tovecimig, shows mixed data in various trials, with a significant upcoming phase 3 ...

As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price ...

Guggenheim initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price target Discover the Best Stocks and Maximize Your ...

Fintel reports that on February 19, 2025, Piper Sandler initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Overweight recommendation. Analyst Price Forecast Suggests 232.44% Upside As ...

Compass Therapeutics, Inc. (CMPX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...